Evaxion A/S
EVAXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeEvaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. With a market capitalization of $33.9M, it sits in micro-cap territory. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Market Cap
$33.9M
Beta
0.51
P/E (TTM)
—
P/E (Fwd)
-250.67
EPS (TTM)
$-1.02
EPS (Fwd)
$-0.01
ROE
-109.9%
ROA
-26.0%
Cash
$14.0M
Total Debt
$7.1M
Free CF
-$5.5M
52W Change
-36.2%
Annual Financials
Cash vs Debt
Where EVAX stands vs its 150-day and 200-day moving averages
As of the October 19, 2026 close, EVAX finished 19.14% below its 150-day moving average ($3.50) and 20.95% below its 200-day moving average ($3.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EVAX overbought or oversold?
At the October 19, 2026 close, EVAX's RSI(14) was 21.9, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $14.0M in cash comfortably exceeding the $7.1M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$5.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -109.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of 0.51 suggests EVAX is a less volatile holding compared to the broader index. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Evaxion A/S and its sector.